How much does Osimertinib/Tagressa cost after medical insurance reimburses it? Interpretation of the latest prices and policies in 2025

With the launch of Osimertinib/Tagressa in China, more and more patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) can benefit from the efficacy of this drug. Especially after the expansion of China's medical insurance coverage, patients' financial burden when purchasing osimertinib has been significantly reduced. However, due to the high price of the original drug Osimertinib, many patients still want to know how to reduce treatment costs through medical insurance policies.

The original drug of Osimertinib is produced by AstraZeneca (AstraZeneca). Currently, the commonly used specifications in China include 80mg 30 tablets and 40mg 30 tablets. According to market information, the price of osimertinib is roughly between 4,000 yuan and 6,000 yuan. The specific price is affected by regional and pharmacy policies. For patients who require long-term medication, this price may put some pressure on the financial situation.

Although the original drug of osimertinib is more expensive, many patients still choose to use this drug due to its excellent efficacy. With the adjustment of medical insurance policies, osimertinib has been included in the scope of medical insurance reimbursement. Patients can reduce drug costs through medical insurance reimbursement, thereby reducing the burden of treatment.

According to the latest medical insurance policy, osimertinib has been included in China’s Class B medical insurance directory. For eligible patients, medical insurance can reimburse part of the cost. According to the medical insurance payment standards in different regions, patients can pay part of the drug cost through the medical insurance card, and the remaining part is borne by the patient personally. It is worth noting that the specific proportion and cost reimbursement limit of medical insurance reimbursement may vary according to the patient's treatment plan and the medical insurance policy of the region. Therefore, when purchasing drugs, patients are advised to first consult the hospital or pharmacy for specific reimbursement ratios.

Reference materials:https://go.drugbank.com/drugs/DB09330